Previous close | 0.0540 |
Open | 0.0550 |
Bid | 0.0550 x 25215400 |
Ask | 0.0590 x 5549800 |
Day's range | 0.0550 - 0.0560 |
52-week range | 0.0440 - 0.1500 |
Volume | |
Avg. volume | 224,919 |
Market cap | 17.28M |
Beta (5Y monthly) | 0.85 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0190 |
Earnings date | 25 Aug 2022 - 29 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
AdAlta Limited (ASX:1AD) and Carina Biotech Pty Ltd have entered a collaboration agreement to develop next-generation i-body enabled CAR-T cells, with the potential to bring CAR-T cell therapy to treat a far greater range of cancers than the small number of blood cancers that has been achieved today.